Viracta Therapeutics, Inc. — Net Income by Fiscal Year

15 fiscal years, as filed with the SEC; every row links its evidence fact.

Cite as: FACTANKER, https://factanker.com/entity/6dac3e4e-c3f8-4dc5-8e48-2f0cd4d8c9a8/serie/net-income

Fiscal year	Net Income	Period	Evidence
FY 2023	$-51.1M	2023-01-01 – 2023-12-31	evidence 0000950170-24-027982
FY 2022	$-49.2M	2022-01-01 – 2022-12-31	evidence 0000950170-23-007905
FY 2021	$-114.8M	2021-01-01 – 2021-12-31	evidence 0000950170-22-003991
FY 2020	$-19.0M	2020-01-01 – 2020-12-31	evidence 0000950170-22-003991
FY 2019	$-13.6M	2019-01-01 – 2019-12-31	evidence 0001193125-21-091167
FY 2018	$-26.6M	2018-01-01 – 2018-12-31	evidence 0001564590-19-006828
FY 2017	$-35.5M	2017-01-01 – 2017-12-31	evidence 0001564590-18-005146
FY 2016	$-38.0M	2016-01-01 – 2016-12-31	evidence 0001564590-17-003862
FY 2015	$-36.7M	2015-01-01 – 2015-12-31	evidence 0001564590-16-014612
FY 2014	$-43.0M	2014-01-01 – 2014-12-31	evidence 0001564590-15-001589
FY 2013	$-34.6M	2013-01-01 – 2013-12-31	evidence 0001193125-14-086649
FY 2012	$-44.0M	2012-01-01 – 2012-12-31	evidence 0001193125-13-105232
FY 2011	$-20.1M	2011-01-01 – 2011-12-31	evidence 0001193125-12-114990
FY 2010	$-24.6M	2010-01-01 – 2010-12-31	evidence 0001193125-12-114990
FY 2009	$-40.2M	2009-01-01 – 2009-12-31	evidence 0001193125-12-114990

Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).

Viracta Therapeutics, Inc. — all facts · Revenue · Operating Income